Get the Stockscreener App
120.39
3.58%
4.16
After Hours:
120.50
0.11
+0.09%
Palvella Therapeutics Inc stock is traded at $120.39, with a volume of 261.55K.
It is up +3.58% in the last 24 hours and down -6.38% over the past month.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
See More
Previous Close:
$116.23
Open:
$118.13
24h Volume:
261.55K
Relative Volume:
0.84
Market Cap:
$1.71B
Revenue:
$1.30M
Net Income/Loss:
$-35.78M
P/E Ratio:
-18.35
EPS:
-6.5624
Net Cash Flow:
$-22.82M
1W Performance:
+5.39%
1M Performance:
-6.38%
6M Performance:
+108.68%
1Y Performance:
+341.47%
1-Day Range:
$116.80
$123.94
1-Week Range:
$109.36
$123.94
52-Week Range:
$18.23
$151.18
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Name
Palvella Therapeutics Inc
Sector
Industry
Phone
(484) 253-1461
Address
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
120.39 | 1.65B | 1.30M | -35.78M | -22.82M | -6.5624 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Initiated | Mizuho | Outperform |
| Dec-05-25 | Initiated | BTIG Research | Buy |
| Dec-04-25 | Initiated | Craig Hallum | Buy |
| Nov-19-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-09-25 | Initiated | Oppenheimer | Outperform |
| Aug-06-25 | Initiated | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Apr-09-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-26-25 | Initiated | Stifel | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-20-25 | Initiated | Canaccord Genuity | Buy |
| Feb-05-25 | Initiated | TD Cowen | Buy |
| Dec-26-24 | Initiated | H.C. Wainwright | Buy |
| Dec-18-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-30-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-19 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Initiated | Jefferies | Buy |
| Jan-16-18 | Reiterated | H.C. Wainwright | Buy |
| May-30-17 | Initiated | Rodman & Renshaw | Buy |
| Aug-05-16 | Resumed | ROTH Capital | Buy |
| Aug-12-15 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-15 | Initiated | Oppenheimer | Outperform |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
View All
Palvella Therapeutics Inc Stock (PVLA) Latest News
Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal - The Motley Fool
Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal - The Motley Fool
Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026 - Sahm
Director Buys $500,000 Worth of Palvella Therapeutics Shares After Phase 3 Win - AOL.com
European Patent Office grants Palvella patent for QTORIN rapamycin - MSN
H.C. Wainwright raises Palvella Therapeutics stock price target to $270 By Investing.com - Investing.com Canada
Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $270.00 at HC Wainwright - MarketBeat
European Patent Office Grants Palvella Patent for QTORIN Rapamycin - MyChesCo
Palvella appoints Jennifer McDonough as market access head By Investing.com - Investing.com Australia
Palvella Therapeutics Appoints Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services - citybiz
Palvella appoints Jennifer McDonough as market access head - Investing.com
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services - The Manila Times
Palvella Therapeutics (PVLA) to Release Earnings on Monday - MarketBeat
Palvella Therapeutics (PVLA) Receives a Rating Update from a Top Analyst - The Globe and Mail
Rate Cut: Is Palvella Therapeutics Inc a play on infrastructure spending2026 Trade Ideas & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Aug Shorts: Is Palvella Therapeutics Inc stock forming a cup and handle2026 Dividend Review & Low Risk Investment Opportunities - baoquankhu1.vn
Palvella Completes Phase 2 Trial of QTORIN Rapamycin for Rare Skin Disorder - MSN
Palvella Therapeutics COO sells $507k in shares By Investing.com - Investing.com India
Market Outlook: Can Palvella Therapeutics Inc lead its sector in growthWeekly Risk Summary & Advanced Technical Signal Analysis - baoquankhu1.vn
Palvella Therapeutics COO sells $507k in shares - Investing.com
Kathleen Goin Sells 4,302 Shares of Palvella Therapeutics (NASDAQ:PVLA) Stock - MarketBeat
Market Trends: Will Palvella Therapeutics Inc benefit from rising consumer demandPortfolio Value Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Palvella Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | PI6 | US6979471090 - marketscreener.com
Topical statins show promise for rare skin disease in new review - MSN
Clear Street initiates coverage of Palvella Therapeutics (PVLA) with buy recommendation - MSN
Fred Alger Management LLC Increases Stock Holdings in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics: A Potential First-In-Class Therapy In A Rare Dermatology Market - Seeking Alpha
Palvella receives European patent for rapamycin gel formulation By Investing.com - Investing.com India
Palvella Therapeutics stock price target maintained at $220 by Clear Street - Investing.com Nigeria
Palvella Therapeutics (NASDAQ:PVLA) Earns Buy Rating from Chardan Capital - MarketBeat
Palvella Therapeutics launches awareness campaign for rare lymphatic disease - MSN
Palvella Therapeutics stock price target maintained at $220 by Clear Street By Investing.com - Investing.com India
Palvella Therapeutics Launches Awareness Campaign for Rare Lymphatic Disease - MyChesCo
Palvella receives European patent for rapamycin gel formulation - Investing.com
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin - GlobeNewswire
First Light Asset Management LLC Buys New Holdings in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Apis Capital Advisors LLC Makes New Investment in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Suvretta Capital Management LLC Boosts Stock Position in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Shares Down 8.7%Should You Sell? - MarketBeat
Palvella launches disease awareness campaign for rare lymphatic condition - Investing.com Nigeria
Quarterly Earnings: Can Palvella Therapeutics Inc lead its sector in growth2026 Price Swings & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Chipmakers Recap: Can Palvella Therapeutics Inc deliver alphaQuarterly Market Summary & Low Drawdown Investment Ideas - baoquankhu1.vn
Palvella launches disease awareness campaign for rare lymphatic condition By Investing.com - Investing.com South Africa
Palvella Therapeutics stock rating maintained at Buy by Clear Street - Investing.com Nigeria
Palvella Therapeutics Inc Stock (PVLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):